apples to apples, not to oranges sir
$8 on 01.30.2013, subsequent reverse split 1:4.5 = $36 equivalent today
prior to 01.30.2013, ran higher than $8, even higher than $36 equivalent today
was even higher equivalent for those who experienced 1:15 reverse split
if someone bought long in late 2012 to 01.30.2013,
ask them if these facts are deceptive
first time buyers at $1.50 may not care about history, perhaps they should
hope you sold shares at peaks
count on more fundraisers
Let's set the record straight sts...your sp is full of crapola. I've been in Celsion prior to Proleive going to BSX. Since THAT time CLN/CLSN has never been 36. CLN went to 2.2something with the BSX buy. The Heat Study generated a sp high of 9.something before the failure. Maybe in the late '90's pre dotcom blowout it was trading at your 36, however, CMGI for example, was trading @ 200+, CMGI who?? I'm thinking your factoring the r/s's over the years which is fair albeit deceiving for new investors. Results always trump all other factors, i.e. short rhetoric, and results are getting better. Imo, if you research and educate yourself about CLSN's pipelines you will come to the conclusion that this co.'s sp is SEVERLY undervalued. Carl
This will give me one last time to add some cheap shares if it happens. With the results they've been getting with their TheraPlas/GEN-1 and TheraSilence/GEN-2 there is still a very good chance of multiple collaborations happening.
problem with D I L U T I O N strategy
they didn't go bigtime when stock price was $36
best to issue 1m shares @36, limit impact to shareholders
rather than issue 5m multiple times @ lower prices
Keep in mind Genetech's Phase 3 AURELIA study passed and GEN-1 plus Doxil is already showing better results. Just a matter of time before this stock starts it's run.
Possible dilution is the only thing I see holding this back. I suspect there is quite a few people on the sidelines licking their chops waiting for cheap shares. If and that's still an "If" dilution happens I don't think it would take longer than 1 to 3 weeks to get right back to where it was the day of offering or surpass it with clear sailing ahead.
Just think where this stock ends up with ThermoDox and GEN-1 approved not to mention GEN-2 or all the other combinations with ThermoDox and GEN-1.
Sentiment: Strong Buy
In the GOG Study, at the highest dose level, GEN-1 plus Doxil® produced an objective response rate (ORR) of 29%. This compares favorably to the data from the Phase 3 AURELIA trial in platinum-resistant ovarian cancer, which demonstrated that Avastin® plus chemotherapy produced an ORR of 27%. Historical data for trials evaluating Doxil® monotherapy in platinum resistant ovarian cancer suggest an ORR of only 8% to 12%.
Intraperitoneal administration of GEN-1 in platinum-resistant ovarian cancer patients resulted in a significant increase in IL-12 levels in peritoneal fluid samples. IL-12 levels were quantifiable in 91% of evaluable fluid samples collected post GEN-1 treatment. None of the evaluable pre-treatment peritoneal fluid samples had any detectable IL-12 levels.
The IL-12 levels were detectable for at least seven days after GEN-1 treatment.
In comparison to peritoneal fluid, the IL-12 levels in plasma samples (systemic exposure) following GEN-1 treatment were not detectable or were very low in quantity.
Significant increases in levels of IFN-γ, a key downstream mediator of IL-12 action, were observed in peritoneal fluid but not in plasma samples. At least a 5-fold increase above pre-treatment level in IFN- γ was observed in most samples, with the highest increase observed at 120-fold. Similar results were observed with TNF-α levels, with the highest increase observed at 77-fold over pre-treatment control.
Sentiment: Strong Buy
denying future D I L U T I O N reality is being an ostrich
for many bios like celsion, fundraisers = capital = quasi revenue source
leaders could have heavily diluted at $36
instead they waited until after phase III failure and price collapse
You're talking out your #$%$ again. If you knew that you would borrow as much $ as you could and short, but instead like usual your just hoping & assuming which carries no weight.
Please explain to everyone why you're here other than misery loves company since you have ZERO skin in the game.
Early OVATION Readout Offers Encouraging Signs of Efficacy; Reiterate Buy
Celsion either inks a deal or 2 with GEN-1 or GEN-2 and doubles in a day or it dilutes in the 3rd or 4th quarter which makes it healthy for several milestones in the future. Either way is good with me...if dilution happens I will be loading up on cheap shares-prices most likely we will never see again.
Sentiment: Strong Buy
That total was as of 12/31/15. The total as of 3/31/16 will be reported on or before May 15 (or May 16 since May 15 falls on a Sunday).
"These results, while early, are very impressive and speak to the potential of GEN-1 to improve patient outcomes in ovarian cancer," said Ronald D. Alvarez, M.D., Professor, Division of Gynecologic Oncology at the University of Alabama at Birmingham. "In particular, we see improvements across a number of important and meaningful measures used to assess ovarian cancer, which reinforce our confidence in this IL-12 immunotherapy approach and provide a strong rationale for continued development of GEN-1 for the treatment of ovarian cancer."
All patients experienced a dramatic 96% drop in their CA-125 protein levels as of their most recent study visit. CA-125 is used to monitor certain cancers during and after treatment. CA-125 is present in greater concentrations in ovarian cancer cells than in other cells. A 50% reduction in CA-125 levels is considered meaningful. All patients' CA-125 levels were below the standard cutoff level of 35 U/mL.
"These results build on the impressive clinical findings we observed in the GOG Study as well as the translational data from this same study reported earlier this year. As we move closer towards initiating a Phase I/II trial to evaluate the synergistic anti-cancer effects of GEN-1 together with Avastin® and Doxil®, these results also provide strong validation for the potential of GEN-1 in ovarian cancer," said Michael H. Tardugno, Celsion's chairman, president and chief executive officer. "We will continue to evaluate the maturing dataset from the OVATION study, and may evaluate ways to leverage insights from this trial to help accelerate the clinical development of this highly promising therapy and inform the design of future studies."
Sentiment: Strong Buy